Haizheng Pharmaceutical (600267) Recently announced,The company received a notice from the European Drug Administration (EMA),Hekmodmus capsules jointly developed by the company and Spain CINFA obtained the EU listing approval,Become the only Hitmodimi imitation drug in the EU market。The listing of this product will bring a positive impact on the sales of the company's finished medicine in the European market。  
At the same time,Haizheng Pharmaceutical also signed the "Agreement on Co -Establishing Anti -Chemical Research and Development Center" with Beijing on August 24,Establish an anti -chemical drug research and development center by both parties。The performance period of the agreement is from stake sports betting appAugust 2010 to July 2020。 
 Stake Sports BettingAccording to the agreement,The two parties will build a joint anti -chemical drug research and development center; the creation of anti -chemical new drugs,Including the development of a type of new drugs; the development of key technologies for anti -chemical drugs; the development of industrialization technology of anti -chemical drugs:,Poison Drug Institute is mainly responsible for the development of varieties,Including drug design、Pharmacology and other studies,New medicine discovery、Kitchen screening、Pentalology、Research on toxicity and pharmacokinetics,Pharmacokinetics Research,Safety Evaluation Research; Hisheng Pharmaceuticals is responsible for the research release large process research and industrialization stake sports betting apptechnology stake online sports bettingresearch,and produce a new drug certificate for approval,and establish an independent organizational structure and management mechanism for anti -chemical drugs。